The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

Nestlé is making moves in the weight-loss market with the launch of its new protein shots in the US, designed specifically for individuals using weight-loss medications like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

This initiative marks the company’s latest effort to capitalise on the growing demand for weight-loss products amid an expanding obesity drug market.

The newly introduced Boost Pre-Meal Hunger Support shots are aimed at suppressing appetite and promoting a sense of fullness. Nestlé claims that these drinks can stimulate a natural response in the body similar to the effects of GLP-1, a hormone that curbs appetite and enhances satiety.

The shots are recommended for consumption up to 30 minutes before meals, aligning with the timing of GLP-1 injections.

Each shot contains 10g of whey protein, 45 calories, 1g of sugar and is fat-free.

The product is priced at approximately $10.99 for a pack of four and is available on platforms like Amazon and select CVS stores.

The weight-loss drug market is projected to reach a $150 billion annually within the next decade, presenting a lucrative opportunity for food manufacturers.

Nestlé's entry into this segment follows its earlier introduction of a line of frozen pizzas and protein-enriched pastas tailored for consumers on weight-loss medications.